A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Phase 2Active Not RecruitingNCT05217446

Pfizer107 enrolled

Overview

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that: * is metastatic (spread to other parts of the body); * has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR) * has a certain type of abnormal gene called "BRAF" and; * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic as an intravenous (IV) infusion (given directly into a vein) at the study clinic. In addition, half of the participants will take encorafenib by mouth at home every day and cetuximab by IV infusion at the study clinic. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

107

Conditions

Metastatic Colorectal Cancer

Interventions

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Locally confirmed microsatellite instability-high/ deficient mismatch repair (MSI-H/dMMR) stage IV colorectal carcinoma * Locally confirmed BRAF V600E mutation in tumor tissue or blood * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have not received prior systemic regimens for metastatic disease. * Measurable disease per RECIST 1.1 * Adequate organ function Exclusion Criteria: * Colorectal adenocarcinoma that is RAS mutant or for which RAS mutation status is unknown * Known active central nervous system metastases and/or carcinomatous meningitis; leptomeningeal disease * Immunodeficiency or active autoimmune disease requiring systemic treatment in the past 2 years * Presence of acute or chronic pancreatitis * Clinically significant cardiovascular diseases (eg, thromboembolic or cerebrovascular accident events ≤ 12 wks prior) * Received a live or live-attenuated vaccine within 30 days of planned start of study medication * Previous treatment with any selective BRAF inhibitor (eg, encorafenib, dabrafenib, vemurafenib, XL281/BMS-908662) or any epidermal growth factor receptor (EGFR) inhibitor (eg, cetuximab, panitumumab). * Previous treatment with an immune checkpoint inhibitor (eg, anti-programmed cell death \[PD-1\], anti-PD-L1 or anti-PD-L2 agent); or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).

Locations (57)

Mayo Clinic Building - Phoenix

Phoenix, Arizona, United States

Mayo Clinic Hospital

Phoenix, Arizona, United States

Mayo Clinic

Scottsdale, Arizona, United States

Mount Sinai Cancer Center

Miami Beach, Florida, United States

The West Clinic, PLLC dba West Cancer Center

Germantown, Tennessee, United States

Outcomes

Primary Outcomes

Progression-free Survival (PFS)

PFS per investigator, defined as the time from randomization until PD based on investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause, whichever occurs first:

Time frame: Duration of study, approximately 45 months

Secondary Outcomes

Incidence of adverse events

Incidence and severity of AEs graded according to the NCI CTCAE v4.03: encorafenib and cetuximab + pembrolizumab (Arm A) vs pembrolizumab (Arm B)

Time frame: Duration of study, approximately 45 months

Overall Survival (OS)

OS is defined as the time from the date of randomization to the date of death due to any cause: encorafenib and cetuximab + pembrolizumab (Arm A) vs pembrolizumab (Arm B)

Time frame: Duration of study, approximately 45 months

Objective Response (OR)

OR is defined as a CR or PR per RECIST version 1.1 recorded from the date of randomization until date of first documentation of PD, death, or start of new anti-cancer therapy: encorafenib and cetuximab + pembrolizumab (Arm A) vs pembrolizumab (Arm B)

Time frame: Duration of study, approximately 45 months